Get started
MIRUM PHARMACEUTICALS INCMIRUM PHARMACEUTICALS INCMIRUM PHARMACEUTICALS INC

MIRUM PHARMACEUTICALS INC

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Bonds

MIRM chart


Full chart

MIRM upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪46.99 B‬ MXN
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−40.74 MXN
Net income (FY)
‪−2.78 B‬ MXN
Revenue (FY)
‪3.17 B‬ MXN
Shares float
‪38.32 M‬
Beta (1Y)
0.70

Employees


Employees (FY)
264
Change (1Y)
+68 +34.69%
Revenue / Employee (1Y)
‪11.99 M‬ MXN
Net income / Employee (1Y)
‪−10.51 M‬ MXN

About Mirum Pharmaceuticals, Inc.


Sector
Health Technology
CEO
Christopher Peetz
Headquarters
Foster City
Website
mirumpharma.com
Founded
2018
FIGI
BBG0121CJQL5
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The firm focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its products include Maralixibat and Volixibat. The company was founded by Niall O'Donnel, Michael Grey and Christopher Peetz in May 2018 and is headquartered in Foster City, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

MIRM news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

MIRM highest yielding bonds


MIRM5806400
Mirum Pharmaceuticals, Inc. 4.0% 01-MAY-2029
Yield to maturity
−4.22%
Maturity date
May 1, 2029

Explore more bonds 

Frequently Asked Questions


The current price of MIRM is 902.37 MXN — it has increased by 14.49% in the past 24 hours. Watch MIRUM PHARMACEUTICALS INC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BMV exchange MIRUM PHARMACEUTICALS INC stocks are traded under the ticker MIRM.
We've gathered analysts' opinions on MIRUM PHARMACEUTICALS INC future price: according to them, MIRM price has a max estimate of 1,505.90 MXN and a min estimate of 1,017.50 MXN. Watch MIRM chart and read a more detailed MIRUM PHARMACEUTICALS INC stock forecast: see what analysts think of MIRUM PHARMACEUTICALS INC and suggest that you do with its stocks.
MIRM reached its all-time high on Dec 10, 2024 with the price of 902.37 MXN, and its all-time low was 282.55 MXN and was reached on Aug 19, 2021. View more price dynamics on MIRM chart.
See other stocks reaching their highest and lowest prices.
MIRM stock is 12.65% volatile and has beta coefficient of 0.70. Track MIRUM PHARMACEUTICALS INC stock price on the chart and check out the list of the most volatile stocks — is MIRUM PHARMACEUTICALS INC there?
Today MIRUM PHARMACEUTICALS INC has the market capitalization of ‪46.89 B‬, it has decreased by −5.33% over the last week.
Yes, you can track MIRUM PHARMACEUTICALS INC financials in yearly and quarterly reports right on TradingView.
MIRUM PHARMACEUTICALS INC is going to release the next earnings report on Mar 5, 2025. Keep track of upcoming events with our Earnings Calendar.
MIRM earnings for the last quarter are −5.91 MXN per share, whereas the estimation was −8.86 MXN resulting in a 33.25% surprise. The estimated earnings for the next quarter are −5.64 MXN per share. See more details about MIRUM PHARMACEUTICALS INC earnings.
MIRUM PHARMACEUTICALS INC revenue for the last quarter amounts to ‪1.78 B‬ MXN, despite the estimated figure of ‪1.62 B‬ MXN. In the next quarter, revenue is expected to reach ‪2.01 B‬ MXN.
MIRM net income for the last quarter is ‪−280.48 M‬ MXN, while the quarter before that showed ‪−451.91 M‬ MXN of net income which accounts for 37.93% change. Track more MIRUM PHARMACEUTICALS INC financial stats to get the full picture.
No, MIRM doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jan 20, 2025, the company has 264.00 employees. See our rating of the largest employees — is MIRUM PHARMACEUTICALS INC on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. MIRUM PHARMACEUTICALS INC EBITDA is ‪−1.39 B‬ MXN, and current EBITDA margin is −52.76%. See more stats in MIRUM PHARMACEUTICALS INC financial statements.
Like other stocks, MIRM shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade MIRUM PHARMACEUTICALS INC stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So MIRUM PHARMACEUTICALS INC technincal analysis shows the strong buy rating today, and its 1 week rating is strong buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating MIRUM PHARMACEUTICALS INC stock shows the strong buy signal. See more of MIRUM PHARMACEUTICALS INC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.